Trials / Terminated
TerminatedNCT06024174
A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors
Phase 1/2 Open-label Study of BMS-986466 in Combination With Adagrasib With or Without Cetuximab in Participants With KRAS G12C-mutant Advanced Solid Tumors
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 5 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find a safe, tolerable, and efficacious dose of BMS-986466 when given orally, in combination with adagrasib with or without cetuximab in participants with advanced KRAS G12C-mutant non-small cell lung cancer (NSCLC), pancreatic duct adenocarcinoma (PDAC), biliary tract cancer (BTC), or colorectal cancer (CRC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986466 | Specified dose on specified days |
| DRUG | Adagrasib | Specified dose on specified days |
| DRUG | Cetuximab | Specified dose on specified days |
Timeline
- Start date
- 2023-11-09
- Primary completion
- 2024-05-13
- Completion
- 2024-05-13
- First posted
- 2023-09-06
- Last updated
- 2025-07-22
- Results posted
- 2025-07-22
Locations
9 sites across 5 countries: United States, Australia, Finland, France, Israel
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06024174. Inclusion in this directory is not an endorsement.